Efgartigimod is entering a Phase 3 clinical trial after data from a proof-of-concept Phase 2 trial showed it outperformed a placebo at easing symptoms and signs of primary Sjögren’s disease, the treatment’s developer said. Argenx shared the data at the European Congress of Rheumatology (EULAR) 2025, held June 11-14 in Barcelona, in a presentation, “Treatment of […] The post Efgartigimod in Phase 3 testing for Sjogren’s as data show promise appeared first on Sjogren's Syndrome News.
